AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6734389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked Carrot
Number of subjects: 10
Study 6734389 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Carrot
Number of subjects: 10
Study 6734389 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 10
Study 6734389 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 10
Study 31867724 — intervention group
Group type: EXPERIMENTAL
Intervention: TUN+CTG (test group; n=20)
Number of subjects: 39
Study 31867724 — intervention group
Group type: COMPARATOR
Intervention: CAF+CTG (control group; n=19)
Number of subjects: 39
Study 28817437 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by gastrectomy with D1+ lymphadenectomy
Number of subjects: 636
Study 26932132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Fitness intervention
Number of subjects: 65
Study 26932132 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 65
Study 24622150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance tests including episodic memory, numeracy, and a modified version of the Mini-Mental State Examination
Number of subjects: 1451
Study 24622150 — intervention group
Group type: EXPERIMENTAL
Intervention: Models controlling for education, health status, and social and economic activity
Number of subjects: 1451
Study 22077962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% WBI-1001 cream applied twice daily for 12 weeks
Number of subjects: 61
Study 22077962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% WBI-1001 cream
Number of subjects: 61
Study 22077962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20550840 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC (Activity Bursts in the Classroom) for Fitness program
Number of subjects: 5
Study 17659065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 117
Study 16271652 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT collaborative care program
Number of subjects: 450
Study 16271652 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 450
Study 11863301 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (400 mg, one dose daily for 3 days, starting 12 hours before the flight)
Number of subjects: 300
Study 11863301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) (one dose of enoxaparin injected between 2 and 4 hours before the flight, weight-adjusted 1,000 IU per 10 kg of body weight)
Number of subjects: 300
Study 11863301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 300
Study 10215215 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 79
Study 10215215 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (25 degrees C)
Number of subjects: 79
Study 7877544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20‐40 mg/day)
Number of subjects: 25
Study 7877544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2227075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxofylline (100 mg as a single dose over 10 min)
Number of subjects: 14
Study 2227075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxofylline (400 mg given twice daily for 5 days)
Number of subjects: 14
Study 2227075 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 14
Study 1036709 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg raubasin
Number of subjects: 30
Study 1036709 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg bencyclan
Number of subjects: 30
Study 1036709 — intervention group
Group type: COMPARATOR
Intervention: salt solution (placebo)
Number of subjects: 30
Study 30171497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg twice daily plus Erlotinib 150 mg once daily
Number of subjects: 27
Study 29565149 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (300 Kcals; G1) daily for 23 weeks
Number of subjects: 328
Study 29565149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (300 Kcals; G2) daily for 23 weeks
Number of subjects: 328
Study 25486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy (CBT)
Number of subjects: 488
Study 25486372 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (SRT)
Number of subjects: 488
Study 25486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and Sertraline (COMB)
Number of subjects: 488
Study 25486372 — intervention group
Group type: COMPARATOR
Intervention: Pill Placebo (PBO)
Number of subjects: 488
Study 25486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 488
Study 25486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Number of subjects: 488
Study 25486372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure Tasks
Number of subjects: 488
Study 23759749 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-LIPO-5
Number of subjects: 0
Study 23759749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20823726 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 60
Study 20823726 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 18788656 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 226
Study 18788656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 15920183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dartmouth Operative Conditions Scale (DOCS)
Number of subjects: 70
Study 12886915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative music
Number of subjects: 151
Study 12886915 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative music
Number of subjects: 151
Study 12886915 — intervention group
Group type: COMPARATOR
Intervention: Control group (white noise)
Number of subjects: 151
Study 10229289 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 94
Study 10229289 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to insulin therapy
Number of subjects: 94
Study 10229289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic complaints at baseline
Number of subjects: 94
Study 8947995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate (mean daily dose 437 +/- 185 mg, range 150-900 mg)
Number of subjects: 11
Study 8947995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8947995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate
Number of subjects: 11
Study 2006773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline (4.7 to 16.6 mg/kg/day, divided into two doses)
Number of subjects: 6
Study 2006773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29343283 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR) intervention
Number of subjects: 0
Study 29343283 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (no-CCR control)
Number of subjects: 0
Study 27094802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 50
Study 27094802 — intervention group
Group type: COMPARATOR
Intervention: Control (non-users of rosuvastatin)
Number of subjects: 50
Study 24291272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter AVR
Number of subjects: 275
Study 24291272 — intervention group
Group type: COMPARATOR
Intervention: Surgical AVR
Number of subjects: 275
Study 22739802 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bread (3 weeks)
Number of subjects: 20
Study 22739802 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage (3 weeks)
Number of subjects: 20
Study 22739802 — intervention group
Group type: COMPARATOR
Intervention: Soy bread
Number of subjects: 20
Study 22739802 — intervention group
Group type: COMPARATOR
Intervention: Soy beverage
Number of subjects: 20
Study 19846407 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 19846407 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 18950325 — intervention group
Group type: EXPERIMENTAL
Intervention: Callander blade
Number of subjects: 100
Study 18950325 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 100
Study 18950325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both blades
Number of subjects: 100
Study 16883907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshenling (TSL) combined with telmisartan
Number of subjects: 81
Study 16883907 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan alone
Number of subjects: 81
Study 16883907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TSL + telmisartan and telmisartan alone)
Number of subjects: 81
Study 12759473 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) thermal ablation
Number of subjects: 102
Study 12759473 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 102
Study 10864482 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted peer teaching
Number of subjects: 77
Study 10864482 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted learning alone
Number of subjects: 77
Study 10864482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (computer-assisted peer teaching and computer-assisted learning alone)
Number of subjects: 77
Study 8688399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine sustained release capsules (40 mg, 3 times a day for 7 days)
Number of subjects: 95
Study 8688399 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (identical to ritodrine)
Number of subjects: 95
Study 1839656 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg or 5.0 mg/day
Number of subjects: 2702
Study 1839656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during pretreatment phase)
Number of subjects: 2702
Study 6350745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice intervention (not specified in detail)
Number of subjects: 0
Study 6350745 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill Pain scale
Number of subjects: 0
Study 6350745 — intervention group
Group type: EXPERIMENTAL
Intervention: CES‐D Depression scale
Number of subjects: 0
Study 6350745 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Care scale
Number of subjects: 0
Study 31607019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae block combined with oral drug pregabalin
Number of subjects: 60
Study 31607019 — intervention group
Group type: COMPARATOR
Intervention: Oral drug pregabalin
Number of subjects: 60
Study 29394969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose plus rifaximin 550 mg twice daily for 10 days
Number of subjects: 130
Study 29394969 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone 30 ml thrice daily for 10 days
Number of subjects: 130
Study 27685348 — intervention group
Group type: COMPARATOR
Intervention: Massed practice
Number of subjects: 10
Study 27685348 — intervention group
Group type: COMPARATOR
Intervention: Distributed practice
Number of subjects: 10
Study 27685348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (massed and distributed)
Number of subjects: 10
Study 24879581 — intervention group
Group type: EXPERIMENTAL
Intervention: Local bone grafting
Number of subjects: 81
Study 24879581 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone
Number of subjects: 81
Study 22170364 — intervention group
Group type: COMPARATOR
Intervention: DASH diet (28 g beef/d)
Number of subjects: 36
Study 22170364 — intervention group
Group type: COMPARATOR
Intervention: BOLD diet (113 g beef/d)
Number of subjects: 36
Study 22170364 — intervention group
Group type: COMPARATOR
Intervention: BOLD+ diet (153 g beef/d)
Number of subjects: 36
Study 19773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 18
Study 19773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 18
Study 19773670 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 17334957 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 372
Study 17334957 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan 10 mg
Number of subjects: 372
Study 15759245 — intervention group
Group type: EXPERIMENTAL
Intervention: 350G magnet
Number of subjects: 23
Study 15759245 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 23
Study 12792353 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) treatment
Number of subjects: 51
Study 12792353 — intervention group
Group type: COMPARATOR
Intervention: Non-protease inhibitor (non-PI) treatment
Number of subjects: 51
Study 10577698 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy, 60 Gy in 30 fractions in 6 weeks (R6)
Number of subjects: 204
Study 10577698 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy, 60 Gy in 30 fractions in 3 weeks (R3)
Number of subjects: 204
Study 10577698 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy with carboplatin 70 mg/m2/day for 5 days during weeks 1 and 5 (R6C)
Number of subjects: 204
Study 10577698 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with carboplatin 70 mg/m2/day for 5 days during week 1 (R3C)
Number of subjects: 204
Study 8950879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (initially 5 mg daily, increased to 10 mg daily at 24 months)
Number of subjects: 2027
Study 8950879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027
Study 8950879 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 2027
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in TOHP (Trials of Hypertension Prevention)
Number of subjects: 0
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in HPT (Hypertension Prevention Trial)
Number of subjects: 0
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in TOHP
Number of subjects: 0
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in HPT
Number of subjects: 0
Study 6783861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and diuretic agents (Cardiotensin)
Number of subjects: 60
Study 6783861 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release form of beta-blockers and diuretic agents
Number of subjects: 60
Study 6783861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta-blockers and diuretic agents
Number of subjects: 60
Study 31490300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone 10 mg/mL
Number of subjects: 32
Study 31490300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone 40 mg/mL
Number of subjects: 32
Study 31490300 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 32
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hemoglobin (Hb) ≥ 12 g/dl
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MGUS-like profile
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hemoglobin (Hb) ≥ 12 g/dl including depth of response (and MRD)
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MGUS-like signature including depth of response (and MRD)
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MRD negativity
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) rate at 10 years
Number of subjects: 435
Study 30886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease control at 5 years
Number of subjects: 435
Study 28351408 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (sent for five rounds every two weeks)
Number of subjects: 3600
Study 28351408 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 3600
Study 28351408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 3600
Study 26971190 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal coil (ERC) MRI
Number of subjects: 49
Study 26971190 — intervention group
Group type: COMPARATOR
Intervention: Standard non-endorectal coil (non-ERC) MRI
Number of subjects: 49
Study 26971190 — intervention group
Group type: COMPARATOR
Intervention: Augmented non-endorectal coil (non-ERC) MRI
Number of subjects: 49
Study 25099612 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 25-hydroxyvitamin D levels
Number of subjects: 256
Study 22708608 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal alcohol concentration (TAC)
Number of subjects: 22
Study 22708608 — intervention group
Group type: COMPARATOR
Intervention: Breath alcohol concentration (BrAC)
Number of subjects: 22
Study 19477972 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment (treatment group)
Number of subjects: 112
Study 19477972 — intervention group
Group type: COMPARATOR
Intervention: Grinding that did not affect occlusal contacts (control group)
Number of subjects: 112
Study 17264719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation at 0.5-1 vol% end-tidal concentrations
Number of subjects: 5
Study 17264719 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of sevoflurane)
Number of subjects: 5
Study 17264719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation
Number of subjects: 5
Study 15621654 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental analysis using a prototype measuring device for rehabilitation evaluation
Number of subjects: 2
Study 15621654 — intervention group
Group type: COMPARATOR
Intervention: Non-pathological subjects
Number of subjects: 2
Study 11927756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 54
Study 11927756 — intervention group
Group type: COMPARATOR
Intervention: Psychological treatment conditions (collapsed for this study)
Number of subjects: 54
Study 9830233 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium 10 mg
Number of subjects: 40
Study 9830233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7860156 — intervention group
Group type: COMPARATOR
Intervention: Hygiene education intervention focusing on personal and domestic hygiene practices, including handwashing and disposal of faeces, conducted over 3 months.
Number of subjects: 2082
Study 7860156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2082
Study 2476624 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (1 mg, intravenously)
Number of subjects: 23
Study 6181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 9
Study 6181 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 9
Study 31239466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative model with distance-based connection probability
Number of subjects: 0
Study 31239466 — intervention group
Group type: COMPARATOR
Intervention: Watts-Strogatz (WS) model
Number of subjects: 0
Study 31239466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative model
Number of subjects: 0
Study 27855270 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + LLLT
Number of subjects: 22
Study 27855270 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 22
Study 26114854 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week multi-disciplinary lifestyle intervention (physical activity, nutrition education, cognitive behavioural therapy)
Number of subjects: 43
Study 26114854 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 43
Study 23866761 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea mouthwash
Number of subjects: 44
Study 23866761 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 44
Study 22146117 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP therapy
Number of subjects: 56
Study 22146117 — intervention group
Group type: COMPARATOR
Intervention: Gourmet cooking course
Number of subjects: 56
Study 19203221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived cells (BMC) therapy
Number of subjects: 0
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology (ASCUS+)
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR for carcinogenic HPV
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination testing (carcinogenic HPV testing or cytology)
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2 alone
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCUS+ cytology
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination testing
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 positivity
Number of subjects: 610
Study 16702369 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of posttreatment CIN2+
Number of subjects: 610
Study 15274670 — intervention group
Group type: EXPERIMENTAL
Intervention: KC 11458 (8 mg t.d.s. for 8 days)
Number of subjects: 29
Study 15274670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11742880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 22
Study 11742880 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 22